Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Breast Cancer Female”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01857193
What this trial is testing

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 132
Testing effectiveness (Phase 2)Ended earlyNCT00006121
What this trial is testing

Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 18
Early research (Phase 1)Study completedNCT02262455
What this trial is testing

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Who this might be right for
Ovarian CancerFallopian Tube CancerEndometrial Cancer+1 more
Santa Maria Biotherapeutics 32
Early research (Phase 1)Study completedNCT02046421
What this trial is testing

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Male Breast CancerRecurrent Breast CancerRecurrent Fallopian Tube Cancer+5 more
University of Chicago 31
Large-scale testing (Phase 3)Looking for participantsNCT05696626
What this trial is testing

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Who this might be right for
Metastatic Breast Cancer
LeonaBio 600
Early research (Phase 1)Study completedNCT00381173
What this trial is testing

ZYC300 Administered With Cyclophosphamide Pre-Dosing

Who this might be right for
Breast CancerOvarian CancerProstate Cancer+2 more
Eisai Inc. 22
Testing effectiveness (Phase 2)Ended earlyNCT00372996
What this trial is testing

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer 219
Early research (Phase 1)Ended earlyNCT03746431
What this trial is testing

[225Ac]-FPI-1434 Injection

Who this might be right for
Advanced Solid TumoursEndometrial CancerCervical Cancer+7 more
Fusion Pharmaceuticals Inc. 78
Testing effectiveness (Phase 2)Study completedNCT00068341
What this trial is testing

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 74
Testing effectiveness (Phase 2)Looking for participantsNCT04503265
What this trial is testing

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant NeoplasmBreast CancerOvarian Cancer+3 more
AtlasMedx, Incorporated 122
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Early research (Phase 1)Study completedNCT01495663
What this trial is testing

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Who this might be right for
Cancer
Cellectar Biosciences, Inc. 12
Not applicableStudy completedNCT00310089
What this trial is testing

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)UnknownNCT00026442
What this trial is testing

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Pharmatech Oncology
Early research (Phase 1)UnknownNCT00090727
What this trial is testing

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Solid MalignanciesNon-Hodgkin's Lymphoma
Novacea 45
Not applicableUnknownNCT03047889
What this trial is testing

A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast

Who this might be right for
Advanced Breast Cancer
Chinese Academy of Medical Sciences 4,200
Testing effectiveness (Phase 2)UnknownNCT06133088
What this trial is testing

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Who this might be right for
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Zhejiang Cancer Hospital 53
Testing effectiveness (Phase 2)Study completedNCT00365287
What this trial is testing

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Who this might be right for
Breast CancerKidney CancerLeukemia+3 more
Masonic Cancer Center, University of Minnesota 148
Large-scale testing (Phase 3)Active Not RecruitingNCT05078047
What this trial is testing

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Who this might be right for
Lung Cancer MetastaticRenal Cell CarcinomaHead and Neck Cancer+12 more
UNICANCER 646
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Next Page